คุณภาพชีวิตของผู้ป่วยจิตเภทที่ได้รับการรักษาด้วย ยาต้านโรคจิตกลุ่มดั้งเดิมและกลุ่มใหม่ / ศิริยุพา นันสุนานนท์ = Quality of life among schizophrenia patients receiving conventional and novel antipsychotics / Siriyupa Nansunanon
The purposes of this study were to investigate quality of life among schizophrenia patients receiving conventional and novel antipsychotics and to explore factors related to quality of life, namely age, gender, marital status, education level, occupation, income, duration of illness, number of previous hospitalization, severity of symptoms and types of antipsychotics. The subjects of this study consisted of 350 schizophrenia out-patients who were treated at Srithanya Hospital. The subjects on conventional antipsychotics group w ere 316 and 34 subjects on novel antipsychotics groups: clozapine group, risperidone group and olanzapine group were 18, 6 and 10. The instruments were Quality of Life Questionnaire (QLQ) for quality of life and B ref Psychiatric Rating Scale (BPRS) for severity of symptoms. The data were processed to determine percentage, mean, standard deviation, maximum and minimum. F-test, C hi-square test and Stepwise multiple linear regression w ere used for statistical analysis. Results were as follows: 1. Most schizophrenia out-patients on antipsychotics groups rated their total quality of life from moderate to good. The conventional antipsychotics group scored good 49.1% , clozapine group scored moderate 55.6%, risperidone group scored moderate 66.7% and olanzapine group scored good 60%. There were no statistically significant difference in total quality of life Among each group. 2. The factors related to quality of life which statistically significant predicted the total quality of life in the schizophrenia out-patients on antipsychotics groups at 0.01 and 0.05 were severity of symptom s, married patients, high education level and gender.